McClung M - Search Results

1

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM. McClung M, et al. Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Am J Med. 2013. PMID: 23177553 Review.

2

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al. Chesnut CH 3rd, et al. Among authors: mcclung mr. Am J Med. 1995 Aug;99(2):144-52. doi: 10.1016/s0002-9343(99)80134-x. Am J Med. 1995. PMID: 7625419 Clinical Trial.

3

Use of bone densitometry results for decisions about therapy for osteoporosis.

Ettnger B, Miller P, McClung MR. Ettnger B, et al. Among authors: mcclung mr. Ann Intern Med. 1996 Oct 1;125(7):623. doi: 10.7326/0003-4819-125-7-199610010-00021. Ann Intern Med. 1996. PMID: 8815769 No abstract available.

4

Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis.

McClung MR. McClung MR. Bone. 1996 Nov;19(5 Suppl):195S-198S. doi: 10.1016/s8756-3282(96)90165-9. Bone. 1996. PMID: 8922662 Review.

5

Prediction of fracture risk. I: Bone density.

Miller PD, McClung M. Miller PD, et al. Among authors: mcclung m. Am J Med Sci. 1996 Dec;312(6):257-9. doi: 10.1097/00000441-199612000-00003. Am J Med Sci. 1996. PMID: 8969614 Review.

6

Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.

Bone HG, Downs RW Jr, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ. Bone HG, et al. Among authors: mcclung mr. J Clin Endocrinol Metab. 1997 Jan;82(1):265-74. doi: 10.1210/jcem.82.1.3682. J Clin Endocrinol Metab. 1997. PMID: 8989272 Clinical Trial.

7

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd. Stock JL, et al. Among authors: mcclung mr. Am J Med. 1997 Oct;103(4):291-7. doi: 10.1016/s0002-9343(97)00130-7. Am J Med. 1997. PMID: 9382121 Clinical Trial.

8

New developments in osteoporosis.

McClung MR. McClung MR. Compr Ther. 1997 Dec;23(12):798-803. Compr Ther. 1997. PMID: 9403232 Review.

9

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P. McClung M, et al. Ann Intern Med. 1998 Feb 15;128(4):253-61. doi: 10.7326/0003-4819-128-4-199802150-00001. Ann Intern Med. 1998. PMID: 9471927 Clinical Trial.

10

Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice.

McClung MR. McClung MR. Ann Med Interne (Paris). 2000 Sep;151(5):392-8. Ann Med Interne (Paris). 2000. PMID: 11033474 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters